Navigation Links
Intensive Chemotherapy May Be Harmful to Most Older Patients With Acute Myeloid Leukemia
Date:7/28/2010

WASHINGTON, July 28 /PRNewswire-USNewswire/ -- The prognosis for nearly three-quarters of elderly patients on intensive chemotherapy for acute myeloid leukemia (AML) is poor, with a median survival of less than six months, according to a study published online today in Blood, the journal of the American Society of Hematology. AML is the most common form of acute leukemia among adults and is a rapidly growing cancer of the bone marrow that requires immediate treatment. The average age at diagnosis is 67, and more than 12,000 people will be diagnosed with AML this year (according to the National Cancer Institute).

"Recent studies have suggested that intensive chemotherapy might benefit elderly patients with AML, but we found that not to be the case," said Hagop Kantarjian, MD, Chairman of the Leukemia Department at The University of Texas M. D. Anderson Cancer Center in Houston and senior author of the study. "Patients who did not have any of the eight-week mortality predictors we identified in the study may benefit from the more intense treatment, but for the majority of AML patients of advanced age, lower-intensity treatments are a better, less risky option."

Symptoms of AML include fever, frequent infections, tiredness, pale skin, shortness of breath, easy bleeding or bruising, and pain in the bones or joints. Because the disease develops rapidly, doctors usually begin treatment immediately after diagnosis. Treatments for AML include chemotherapy or a transplant with blood cells obtained from the circulating blood or cord blood, though, for most elderly patients, the risks of serious side effects eliminate transplant as a viable option.

As most clinical trials of AML thus far have excluded patients older than 55, physicians have had to infer that treatments that work for younger patients will work for older patients, too. In this study, researchers focused on older patients with AML in order to provide more conclusive information about treatment among this population. Researchers analyzed 446 patients with AML age 70 or older who were given a cytarabine-based intensive chemotherapy regimen between 1990 and 2008. For nearly half of the patients, the therapy was successful in combating the cancer, with 45 percent achieving a complete remission. However, 154 patients (some who were in remission as well as some who were not) died during the first eight weeks after treatment began. Causes of death included both treatment toxicity and ineffective therapy leading to disease progression. The researchers analyzed the patients to identify those most at risk for this eight-week mortality rate and found the following predictive factors:

  • age greater than 80 years
  • three or more genetic abnormalities
  • poor performance as indicated by an ECOG score of 2-4 (Developed by the Eastern Cooperative Oncology Group, a score of zero on this scale indicates a fully active individual with no signs of disease, while a score of five indicates death).
  • creatinine levels greater than 1.3 mg (Creatinine levels are an indicator of kidney function, the organ that filters the blood).

The more of these factors patients had, the poorer their survival outcome with intensive chemotherapy. Among those who did not have any of these risk factors (28 percent), only 16 percent had an eight-week mortality rate as compared with a 71 percent mortality rate among patients with three or more adverse factors (9 percent).

"When doctors and patients are discussing intensive chemotherapy as a treatment option for AML, they must take these mortality risk factors into consideration to determine whether the patient is likely to benefit from this type of treatment," said Dr. Kantarjian.

The American Society of Hematology (www.hematology.org) is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology. ASH provides Blood: The Vital Connection (www.bloodthevitalconnection.org), a credible online resource addressing bleeding and clotting disorders, anemia, and cancer. The official journal of ASH is Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, which is available weekly in print and online.


'/>"/>
SOURCE American Society of Hematology
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cerebral Palsy Course Strengthens CDS Curriculum as Second Disability Intensive Course Offering
2. Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients
3. Study Shows Use of AdvanDxs PNA FISH(TM) Test was Associated with an 82% Reduction in Intensive Care Unit Mortality Rates from Staphylococcus aureus Bloodstream Infections
4. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
5. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
6. Researchers at MD Anderson Show That Positron Emission Mammography (PEM) Helps Evaluate Early Response to Neoadjuvant Chemotherapy
7. Two Studies Evaluated Full-Dose Chemotherapy Regimen and Concurrent Radiation in Treatment of Lung Cancer
8. BSGI Offers Clear View of Breast Tumor Response to Neoadjuvant Chemotherapy
9. Chemosensitivity/Resistance Assay Included as Part of the NCCN Principles of Chemotherapy
10. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
11. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
(Date:6/24/2016)... Maryland (PRWEB) , ... June 24, 2016 , ... ... Angels is actively feeding the Frederick area economy by obtaining investment capital for ... over the past 2½ years that have already resulted in more than a ...
Breaking Medicine News(10 mins):